报价延迟最少15分钟:2026/04/18 03:05 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.4372 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.25/-0.26
|
|
企业价值
14.47M
|
| 资产负债 |
|
每股账面净值
-0.05
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
21.80K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line. |
